View these presentation slides showing data from a recent prospective, randomised controlled phase IIIb study for 4F-PCC.
Oral Anticoagulation Reversal
Declaration of sponsorship
CSL Behring
Resources
Declaration of sponsorship
CSL Behring
Read time: 25 mins
Last updated:12th Mar 2020
Published:12th Feb 2020
In This Section
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
- Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors
- Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease
- Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal
- Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents
- Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies
- Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase IIIb randomised trial
View this educational slide deck which discusses 4F PCC versus plasma in Vitamin K antagonist reversal in a phase 3b open-label randomised trial.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Job number: KCT16-01-0010
Developed by EPG Health for Medthority in collaboration with CSL Behring, with content provided by CSL Behring.
Not intended for Healthcare Professionals outside Europe.